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Hepatocellular carcinoma (HCC) is the sixth 
most common cancer worldwide and is the second 
most common cause of cancer-related death [1, 2]. 
Its poor survival results from pre-existing chronic 
liver disease (CLD), comorbidities, and reduced 
rate of resectability [3]. Portal vein tumor throm-
bosis (PVTT) often complicates the management 
of HCC and is present in 35% to 50% of cases at the 
time of diagnosis. There is no universal consensus 
on how best to treat HCC with PVTT. The West 
AbstrAct
background: The purpose of this study was to evaluate the outcome of stereotactic body radiation therapy (sBrT) in patients 
of unresectable hepatocellular carcinoma (hcc) complicated with portal vein tumor thrombosis (pVTT) who are also unsuit-
able for other locoregional therapies.
Materials and methods: Between May 2018 and January 2020, twenty-nine patients with advanced unresectable hccs, 
treated with sBrT, were enrolled in this retrospective audit. patients of child status a5-B7 and with healthy liver volume, ≥ 
700 ccs were treated. Local control (Lc), overall survival (Os), progression-free survival (pFs), pVTT opening rate, and effect of 
prognostic factors were analyzed. 
results: The median tumor diameter was 8.6 cm (5–14), and the median tumor volume was 275 cc (151–1196). The median 
sBrT dose prescription was 48 Gy in 6 fractions (32–50 Gy in 5–6 fractions). The median follow up was eight months (1–20), 
1-year local control, progression-free survival, and overall survival were 95%, 53.4%, and 60%, respectively. Overall rate of 
grade III toxicity was less than 5%, and the most common toxicity was lymphocytopenia. Tumors of more than 350cc had 
worse Os and pFs when compared to tumors < 350 cc (median Os and pFs of tumors > 350 cc was 4 months and two months, 
p = .01 and .003, respectively). a total of fifteen patients progressed with the disease and the median time to progression was 
two months [1–4].
conclusion: sBrT is safe and provides excellent local control in advanced hcc complicated with pVTT. The out of field failure 
pattern and time to failure in these patients highlights the need for adjuvant systemic therapy after completion of local treat-
ment. Our data warrant the need for multimodality trials in this patient cohort.
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considers it as a systemic disease and offers system-
ic therapy. Sorafenib has been the mainstay of sys-
temic treatment for a long time and has resulted in 
modest survival benefits but a poor overall response 
rate and a high toxicity profile [4, 5]. More recently, 
immunotherapy has been introduced in a big way 
in the management of HCC [6]. There are many 
ongoing trials with nivolumab, ipilimumab, and 
atezolizumab that are addressing the issue of HCC 
with PVTT [7, 8]. The East, on the other hand, is 
more permissible of locoregional treatments along 
with systemic therapy. Recently, surgery has been 
found to be suitable for Vp1, and Vp2 PVTT, that 
is, Vp1, presence of a tumor thrombus distal to, 
but not in, the second-order branches of the portal 
vein; Vp2, presence of a tumor thrombus in the sec-
ond-order branches of the portal vein [9]. Transar-
terial chemoembolization (TACE) or transarterial 
radio embolization (TARE) are options available for 
patients who refuse surgery or who are inoperable. 
Nevertheless, the prognosis of HCC with PVTT 
remains poor. Observation alone results in a me-
dian OS of two months; with sorafenib, it is 4 to 8 
months [4, 10–12]. TACE has a better one-year OS 
when compared to conservative management, as 
reported in the meta-analysis by Xue et al. [13]. In 
their analysis, it was found that the pooled estimate 
for overall survival was significant (HR: 0.44; 95% 
CI: 0.34–0.57; z, 6.22; p = 0.000). The same was 
also confirmed in another meta-analysis by Leng 
et al. [14]. Surgical resection, in a few retrospective 
series, has shown promising results with median 
OS ranging between 6 to 30 months [15]. As PVTT 
is a contraindication for liver transplant, treatment 
strategies that target the recanalization of PVTT 
are required. Stereotactic body radiation therapy 
(SBRT) provides one such option. A Metanalysis by 
Rim et al. [16] concluded that SBRT is a safe treat-
ment option that has a good response rate in treat-
ing HCC with PVTT. Our department conducted 
a retrospective study of unresectable HCC patients 
complicated with PVTT who had failed from other 
locoregional therapies.
Materials and methods
This retrospective review was approved by our 
internal review board, and informed consent was 
taken from all the patients who had undergone 
SBRT.
From May 2018 to January 2020, twenty-nine 
advanced unresectable HCC patients having failed 
from prior locoregional and systemic therapy were 
retrospectively reviewed. Patients with a normal 
liver volume of more than 700 cc and with East-
ern Co-operative Oncology Group (ECOG) per-
formance status of 0–2 were treated with SBRT. 
SBRT was not offered or deferred in patients who 
had a total bilirubin level of more than 3 mg/dL, 
child B8 or higher, ECOG higher than 2, acute viral 
hepatitis, platelets less than 50,000, AST/ALT levels 
of more than five times the normal upper limit, 
PT/INR > 2.2, albumin < 2.8 gm/dL and previous 
liver-directed radiation. SBRT was delivered four 
weeks after TACE and seven days after stopping 
sorafenib. 
Patients characteristics is presented in Table 1.
sBrT treatment planning
In our department, all eligible patients undergo 
respiratory coaching and assessment 4–6 days be-
fore CT simulation. Patients who are capable of 
breath-hold SBRT are treated in normal expira-
tory breath-hold (NEBH) and the ones who are 
not competent, are treated with abdomen compres-
sion along with our novel protocol of synchronized 
4DCT simulation [17]. All Cases were planned us-
ing the MONACO treatment planning system from 
Elekta, Sweden using the volumetric modulated arc 
therapy (VMAT) technique as it is dosimetrically 
superior to dynamic conformal arc [18].
NeBh technique
We acquire a CT in NEBH using Anzai Ver-
sion 6.0, Japan during CT simulation for obtaining 
and indexing a breath-hold four phase-contrast 
CT. Intra- and inter-breath-hold liver movements 
are calculated by taking CT scans at various time 
points, and the same is incorporated in the in-
ternal target volume (ITV). An arterial, late arte-
rial, porto-venous, and delayed phase CT scans 
are taken at 20, 30, 40 seconds, and 5 minutes, 
respectively, after administration of the contrast in-
jection. The delayed phase CT is used to delineate 
all organs at risk (OARs), and perform dose calcu-
lation. The gross tumor volume (GTV) or clinical 
target volume (CTV) is contoured using informa-
tion from all the four phases of the acquired CT 
and is then transferred to the delayed phase CT. An 
ITV is generated by calculating the difference in 
Rishabh Kumar et al. sBrT in advanced hcc with pVTT
575https://journals.viamedica.pl/rpor
the liver position from all the acquired CTs. A de-
partment-specific 5 mm planning target volume 
(PTV) is given on top of the ITV on which the fi-
nal planning and dose calculation takes place. The 
dose constraints and other planning parameters 
used in optimization are provided in the Supple-
mentary File — Table S1. The treatment plan is ac-
cepted when 95% of the PTV receives a minimum 
of 95% of the prescribed dose. The dose prescrip-
tion varied case by case according to the presence 
of normal liver in each patient. The dose varied 
from 35 Gy to 54 Gy in 5 to 6 fractions, refer to the 
Supplementary File — Table S2 for treatment de-
tails. In the treatment room, we place the Anzai 
version 6.0 pressure belt on the same indexed 
location with the same pressure parameters, and 
a breath-hold 3DCBCT is acquired. We use the 
liver boundaries to match the liver, which acts as 
a surrogate for the tumor. OARs are also kept in 
mind during the match process, and if an OAR 
comes inside the high dose PTV then the patient 
is repositioned. The treatment beam is gated in 
breath-hold using the Anzai system.
synchronized contrast 4DcT 
We use our novel protocol to take an arterial 
enhancing, and a delayed phase 4DCT along with 
abdomen compression for patients incapable of 
performing a department desired breath-hold pat-
tern; details of the same are available elsewhere 
[17]. 4DCT is done after confirming that the move-
ment of the liver is less than 1cm by using fluo-
roscopy. The target is contoured on all phases of 
the 4DCT by using information from the arterial 
and delayed phases, and an ITV is generated. The 
delayed phase 4DCT is used for contouring OARs 
and dose calculation. A department-specific 5 mm 
PTV is generated for planning. In the treatment 
room, the patient is positioned with Vaclok, ab-
domen compression belt, and the Anzai pressure 
belt. A 4DCBCT (cone beam CT) is acquired to 
confirm the patient’s treatment position and liver 
motion. The Anzai pressure belt is used to monitor 
the breathing during radiation delivery, and simi-
lar respiratory cycle parameters generated during 
CT simulation are reproduced during treatment 
delivery. In case a change is detected in the breath-
ing cycle during delivery, the beam is automatically 
stopped. Figure S1 in the Supplementary File shows 
a patient set up with an abdomen and chest com-
pression pre-SBRT.
Toxicity assessment and follow-up
Liver function tests were carried out during ra-
diation to monitor any acute treatment-related 
toxicity. Along with the LFTs, complete blood 
chemistry and kidney function tests were done 
at each follow up for toxicity assessment. Toxicity 
was graded using common toxicity criteria and 
adverse events version 5.0. The first follow up after 
SBRT was at one month and after that every two 
months until death. The response assessment was 
table 1. patient characteristics
Patient characteristic N (%) [total patients —29]




















hepatitis B 12 (41.5)
Nash 4 (14)
hepatitis c 6 (20.5)
ethanol 6 (20.5)
No cLD 1 (3.5)
Previous treatment
Tace and sorafenib 11 (38)
sorafenib only 9 (31)
ablation and Tace 9 (31)
ecOG — eastern co-operative Oncology Group; BcLc — Barcelona clinic 
Liver cancer staging; pVTT — portal vein tumor thrombosis; cLD — chronic 
liver disease; Nash — non-alcoholic steatohepatitis; Tace — transarterial 
chemoembolization
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carried out at three months using tumor markers 
[alpha-fetoprotein (AFP) or protein induced by 
vitamin K absence-(PIVKA)] for a biochemical 
response (biochemical response was defined as 
a reduction of tumor markers by 50% or more 
from the baseline) [19] and PET CT or MRI for 
a radiological response; response assessment was 
done using mRECIST criteria version 1.1. A base-
line MRI was also done at one-month post-SBRT 
to understand any RT changes in the liver and to 
differentiate from tumor progression during the 
response assessment at three months. Progression 
within 1 cm of the treated volume was consid-
ered as in-field failure. Any new lesions appear-
ing outside the treated volume were considered 
as out of field failure. Only the index lesion was 
calculated to estimate local control. Any distant 
metastases were also considered as an event for 
progression-free survival.
statistical analysis
Kaplan-Meier method was used to generate the 
local control (LC), progression-free survival (PFS), 
and overall survival (OS). As only the index lesion 
was evaluated for LC, the competing risk model 
was not used. The log-rank test was used for group 
comparisons. Univariate analysis with hazard ratio 
(HR) and 95% confidence interval (estimated by 
Cox proportional hazards regression) was used to 
correlate tumor and patient-related factors to LC, 
PFS, and OS. Factors that were found to be sig-
nificant in univariate analysis were applied to the 
multivariate Cox proportional hazards regression. 
p < 0.05 was considered as statistically significant. 
The median time to tumor progression, OS and PFS 
were also calculated. All calculations were done us-
ing SPSS version 23.
results
After evaluating the twenty-nine patients treated 
between May 2018 and March 2020, it was found 
that the median largest tumor diameter was 8.6cm, 
median GTV was 275 cc, the normal liver vol-
ume was 1302 cc, Median biological effective dose 
(BED) to the PTV was 86.4 Gy, the median dose to 
the normal liver was 13.6 Gy. Detailed results are 
available in the Supplementary File — Table S2. Af-
ter doing a cox proportional analysis for all patients 
and tumor factors, only GTV was significantly as-
sociated with a poor outcome. Patients with GTV 
of more than 350 cc had a poor prognosis. The 
remaining details of patient and tumor character-
istics are available in Table 1 and Table S2. Risk 
factor assessment and their respective p-values are 
presented in the Supplementary File — Table S3.
At a median follow up of 6 months (1–20 
months), the median overall survival (OS) and 
progression-free survival (PFS) was 15 months and 
five months, respectively. The 1-year OS, PFS, and 
Local control (LC) was 53.4%, 31%, and 96%, re-
spectively (corresponding Kaplan Meir Curves can 
be found in Figure 1). The overall response rate 
assessed by Modified Response Evaluation Criteria 
in Solid Tumors (mRECIST) criteria 1.1 at three 
months was 90%, with complete response seen in 
45% and partial response in 45% cases. Biochemi-
cal response at three months (which was defined 
as a more than 50 percent reduction in baseline or 
normalization of tumor marker levels) was 80% 
(Supplementary File — Table S5). There were a total 
of 15 progression events, out of which 14 were out 
of the field, and one was both infield and distant. 
Out of the 14 out-of-field events, four were distant 





















Figure 1. Kaplan-Meier curves, progression-free survival (pFs), overall survival (Os), and local control (Lc) at one year 
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(progression within 1 cm of the treated volume was 
considered as in-field failure, and outside that mar-
gin, as out of field). Four events were both distant 
and out of field. The median time to progression 
was 2 months (1–6 months), and all progression 
events occurred within six months, post-SBRT in 
our patient population. 
Complete recanalization of the portal vein oc-
curred in two patients. Both of them underwent 
a liver transplant and are currently disease-free. 
Hence, the complete recanalization rate in our pa-
tient population was 7%, and a partial response 
radiological response to the PVTT was seen in 
twenty-three of the twenty-nine patients (80%). 
A stable or progressive PVTT was seen in four pa-
tients. Figure 2 shows the complete recanalization 
of the portal vein.
Toxicity 
In general, SBRT delivered to this advanced stage 
patient population was well tolerated. All toxicities 
were graded via common toxicity criteria version 
5.0 (CTC v5.0). The most common toxicity was 
hematological in the form of lymphocytopenia. 
Fifty-five percent of cases had grade 1 to 2 lympho-
cytopenia, and twenty-eight percent cases devel-
oped grade 3 lymphocytopenia. Grade I–II nausea 
vomiting was seen in 53% cases, grade III–V liver 
enzyme elevation was seen only in 2 cases (7%). Ten 
patients developed worsening of the Child-Pugh 
score by more than two at a median follow up of 6 
months, but all these patients also had progressive 
disease. One patient decompensated and developed 
grade I hepatic encephalopathy during radiation 
but later recovered with conservative management. 
None of the cases developed duodenal ulceration 
radiation pneumonitis or classical radiation-in-
duced liver disease. Further details on toxicity are 
available in Table 2.
Discussion
In the current study, SBRT to the tumor and the 
thrombus was generally given to the patients who 
had exhausted all other locoregional treatment op-
tions. Most of them had failed on either TACE or 
RFA or were unresectable due to advanced macro-
vascular invasion. Only two out of the twenty-nine 
patients of HCC with PVTT were treated with up-
front SBRT. The median tumor diameter and me-
dian GTV volume in our study were 8.6 cm and 
275 cc, respectively. This is much higher than previ-
ously published studies [19–21] and comparable to 
a recently published Indian data [22]. Still, we were 
able to achieve an ORR of 90%, with a respectable 
CR of 45% at 3 months. This compares favorably 
to other published data where ORR varying from 
25.2%, Huang et al. [23] to 93%, Matsuo et al. [24] 
have been quoted. In the past poor response to 
radiotherapy, Barcelona Clinic Liver cancer stag-
ing (BCLC) stage, tumor volume more than 350 cc, 
Child-Pugh status, and radiation dose have been 
associated as poor prognostic factors, yet in our 
study, only gross tumor volume of more than 350 cc 
was associated with poor survival and progression, 
none of the other risk factors were found to be sig-
nificant. SBRT achieved an excellent local control 
of 96% in this patient cohort. The six months and 
one year PFS was 37% and 31%, respectively, with 
a median PFS of 5 months. The most common form 
of progression was out of field, with the liver being 
the most common site. This reflects the underlying 
Figure 2. portal vein recanalization. A. The pr-sBrT scan with portal vein tumor thrombosis (pVTT) involving the confluence 
of the portal veins, the same thrombus was extending into the main portal vein a Vp4 thrombus; b. The isodose distribution 
of a full arc the volumetric modulated arc therapy (VMaT) plan; c. contrast-enhanced computed tomography (cecT) at the 
same level showing a complete resolution 6 months post stereotactic body radiation therapy (sBrT). This patient underwent 
a liver transplant and is disease free
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chronic inflammation in the liver, which is prob-
ably carcinogenic. The most common distant site 
involved with metastasis was the lung (seven out of 
the twenty-nine cases).
Interestingly, the median time to progression in 
patients of HCC with PVTT is quite short, and all 
progression events took place within six months. 
Similar results were also noted by Shui et al. [25] 
where all progression events occurred within six 
months of SBRT, and the median time to progres-
sion was 3 months, though, in that study, SBRT 
was used as the first treatment. Even Chopra et al. 
noted that post-SBRT the most common form of 
progression is an out-of-field failure and quoted 
a distant relapse rate of 34% among the twenty-five 
analyzed patients. We experienced a similar distant 
relapse rate of 27% and a liver relapse of 34%. This 
pattern of failure post SBRT signifies the efficacy of 
SBRT in controlling the local disease but also re-
flects the aggressive nature of HCC with PVTT and 
the presence of metastatic/micrometastatic disease 
in cases of PVTT [26]. After assessing the patterns 
of failure and time to progression, it appears that 
patients with PVTT might benefit from multimo-
dality treatment where systemic treatment should 
be started within one month of completion of lo-
cal treatment. Systemic treatment alone results in 
a dismal median OS of 4–6 months with an ORR 
of 3.3% [10] in Asians. Even though close to 50% of 
the patients progressed within six months of SBRT, 
the other 50% did not. Because of that, we had 
a promising six month and one year OS of 83% and 
54%, respectively, with a median OS of 15 months. 
The survival in this study was at the upper end of 
that reported in the literature (Tab. 4) [21, 22, 24, 
25, 27] even when these patients were provided 
with SBRT as a treatment option at last. As we re-
started sorafenib 8–12 weeks after SBRT, we believe 
this might be the reason for early distant progres-
sion in some cases. In the future, we will require tri-
als that start systemic treatment within one month 
of SBRT or any other locoregional treatment.
We did not experience any case of classical ra-
diation induced liver disease (RILD). We observed 
an increase in child score by more than two in ten 
patients, though these cases also had progressive 
disease. No patient with a non-progressive disease 
had an increase of CP score at three months. One 
patient developed hepatic decompensation during 
SBRT after receiving 40 Gy in 4 fractions. He had 
developed grade I hepatic encephalopathy. The pa-
tient recovered in a week, and further radiation was 
abandoned. He ended up with a complete response 
and is still alive. Our patient population received 
a median tumor dose of 86.4 Gy BED with a mean 
normal liver dose of 14 Gy resulting in a toxicity 
profile that compares favorably with the published 
literature [16]. The most common toxicity observed 
was lymphocytopenia, with grade 3 toxicity seen 
table 2. Toxicity (worst grade of toxicity from treatment to 
3 months follow-up)
































Duodenal ulceration 0 0
radiation pneumonitis 0 0
cTc — common toxicity criteria
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in 26% of the patients. We hypothesize that high 
dose per fraction radiation results in direct cell kill 
of lymphocytes in the highly vascular liver, and 
there is inadvertent splenic radiation, which might 
kill the resting splenic lymphocytes in the enlarged 
spleens of CLD patients. Various studies on pan-
creatic radiation [28] and liver SBRT [29, 30] have 
reported the same. A summary of a few studies on 
HCC with PVTT treated with SBRT is seen in the 
discussion (Tab. 4) [19–22, 24, 31].
table 3. Blood changes post stereotactic body radiation therapy (sBrT) (average) in heavily pre-treated cases of 
hepatocellular carcinoma (hcc) with portal vein tumor thrombosis (pVTT) 
Test Baseline During RT 1 month 3 months
Total bilirubin [mg/dL] 1.16 1.22 1.44 1.8
Direct bilirubin [mg/dL] 0.35 0.34 0.52 0.72
aLp [IU/L] 203 200 178 247
aLT [IU/L] 52.3 52.2 53.7 60
asT [IU/L] 81 67 65 68
albumin [g/dL] 3.4 3.35 3.3 3.1
protein [g/dL] 7.4 7.2 7.2 7.3
aLc [thou/cc] 1.3 0.66 1 1.1
aNc [thou/cc] 3.9 5.5 4.4 3.9
aFp [ng/mL] 8159 10104 2462 2017
pIVKa [maU/mL] 30979 9433 4236 4161
aLp — alkaline phosphatase; aLT — alanine aminotransferase; asT — aspartate aminotransferase; aLc — absolute lymphocyte count; aNc — absolute 
neutrophil count; aFp — alpha-fetoprotein; pIVKa — protein induced by vitamin K absence; rT — radiotherapy
table 4. a summary of a few studies on hepatocellular carcinoma (hcc) with portal vein tumor thrombosis (pVTT) treated 





















1 year 2 years CR PR OR LC
Matsuo, 
2013
27 1.5 37 62.5 56 11 N/a WhO 67 71 93 N/a
Matsuo et al. 
2015 [24]
16 5.5 44 50.4 38 19 N/a WhO 62 62 81 N/a
Kang et al. 
2014 [21]
34 4.5 32 60 58 29.4 17 WhO 20.5 52.9 73.4 85.2
Jang et al. 
2016 [20]
37 6 39 60 54 27 15 WhO 16 54 70 86
Xi et al.  
2013 [19]
41 Thrombus 100 48 50 13 N/a mrecIsT 39 75 92 N/a
Lo et al.  
2017 [5]
23 3.4 54 71.2 18.7 N/a N/a mrecIsT N/a N/a N/a N/a
chopra et al. 
2019 [22]
21 9.8 42 47 51 15 11 recIsT N/a N/a N/a 90
Liu et al. 
[31]7




23 mrecIsT N/a N/a N/a 94
present 
study
29 8.6 100 70 54 N/a 15 mrecist 35 52 87 95
pVT — portal vein tumor thrombosis; rT — radiotherapy; eQD2 — equivalent dose in 2Gy fractions; cr — complete response; pr — partial response;  
Or — overall response;  Lc — local control; WhO — World health Organization; recIsT — response evaluation criteria in solid Tumors; mrecIsT — Modified 
response evaluation criteria in solid Tumors; Na — non available
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This review carries the general limitations of 
a retrospective study. Different treatments were 
given to the patient before SBRT, and this may re-
sult in a varied patient population. Two patients 
ended up having a liver transplant as the portal 
vein completely recanalized, and this could repre-
sent a source of bias for the presented data. A well 
designed prospective study is warranted to validate 
the results.
Nevertheless, this study provides a detailed ac-
count of the treatment of HCC with PVTT using 
SBRT by a linear accelerator. It also describes the 
nature of progression, survival, and toxicity profile 
in advanced cases of HCC having large tumors and 
failing from conventional forms of treatment. 
conclusion
SBRT in advanced cases of HCC with PVTT re-
sults in excellent local control, survival, and toxicity 
profile. The short median time to progression and 
out-of-field failures point towards a systemic dis-
ease and warrant early adjuvant systemic treatment. 
Further multimodality trials that incorporate sys-
temic treatment with SBRT or other locoregional 
therapies are necessary. 
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